Watson Pharmaceuticals, Inc, an integrated global specialty pharmaceutical company, has received the Federal Trade Commission (FTC) clearance for the acquisition of Actavis group of companies.
The unanimous vote in support of the transaction follows Watson's agreement to a proposed consent order, pursuant to which Watson has agreed to divest certain products as a condition to obtaining FTC approval. The parties have now obtained all regulatory approvals required to close the transaction. Accordingly, the parties expect to consummate the acquisition in late October or early November.
Under the terms of the consent order with the FTC, Watson and Actavis have agreed to divest a number of marketed and pipeline products Par Pharmaceutical Companies, Inc. and Sandoz.
Subject to the consummation of the transaction between Watson and Actavis, Par Pharma will acquire the products of: Watson's Morphine Sulfate Extended Release capsules; Actavis' Nifedipine Extended Release tablets ; Actavis' Metoclopramide Hydrochloride tablets; Actavis' Fentanyl Transdermal Film; Actavis' Diltiazem Hydrochloride Extended Release capsules
Watson's pending application for Adapalene/Benzoyl Peroxide gel; Watson's pending application for Oxymorphone hydrochloride ER tablets; Watson's pending application for Amphetamine salts ER tablets; Actavis' pending application for Rivastigmine patch; Actavis' pending application for Glipizide ER tablets; Actavis' pending application for Varenicline Tartrate tablets; Actavis' pending application for Oxycodone Hydrochloride ER tablets; Actavis' pending application for Ursodiol tablets; Actavis' development stage Methylphenidate hydrochloride ER tablets.
Subject to the consummation of the transaction between Watson and Actavis, will acquire: Actavis' Bupropion Hydrochloride 150 mg. ER tablets; Actavis' Lorazepam tablets; Actavis' Diltiazem Hydrochloride ER capsules; Watson's pending application for Dextromethorphan Hydrobromide /Quinidine Sulfate
Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on urology and women's health.